Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
47.04
+0.55 (1.18%)
At close: Jul 8, 2025, 4:00 PM
47.07
+0.03 (0.06%)
After-hours: Jul 8, 2025, 7:59 PM EDT
BMY Revenue
Bristol-Myers Squibb Company had revenue of $11.20B in the quarter ending March 31, 2025, a decrease of -5.60%. This brings the company's revenue in the last twelve months to $47.64B, up 4.62% year-over-year. In the year 2024, Bristol-Myers Squibb Company had annual revenue of $48.30B with 7.32% growth.
Revenue (ttm)
$47.64B
Revenue Growth
+4.62%
P/S Ratio
2.00
Revenue / Employee
$1,396,950
Employees
34,100
Market Cap
95.73B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
BMY News
- 15 hours ago - June Readers Tagged 13 Ideal Dividend Dogs From 16 "Safer" Out Of 38 ReFa/Ro - Seeking Alpha
- 17 hours ago - Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others - CNBC
- 1 day ago - 2 Wonderful Dividends At Bargain Basement Prices - Seeking Alpha
- 7 days ago - Bristol-Myers Squibb: Strong Launch Portfolio Amid Market Reset - Seeking Alpha
- 9 days ago - Bristol-Myers Squibb: You Might Wish You Bought More Now (Upgrade) - Seeking Alpha
- 12 days ago - U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels - Business Wire
- 14 days ago - Cigna sues Bristol Myers over alleged monopoly for multiple myeloma drug Pomalyst - Reuters
- 14 days ago - 10 'Safer' Dividend Buys Of Barron's Better Bets Than T-Bills For June - Seeking Alpha